Evidence map›Paper›PMID 39315953›Full record

ArticleJournal of natural products2024

Isolation and Characterization of the Cyanobacterial Macrolide Glycoside Moorenaside, an Anti-Inflammatory Analogue of Aurisides Targeting the Keap1/Nrf2 Pathway.

Fatma H Al-Awadhi, Sofia Kokkaliari, Ranjala Ratnayake, Valerie J Paul, Hendrik Luesch

Abstract read
In one paragraph

Article in Journal of natural products, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Marine natural products.Natural product reports · 2026
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Fatma H Al-AwadhiDepartment of Medicinal Chemistry and Center for Natural Products, Drug Discovery and Development (CNPD3), University of Florida, Gainesville, Florida 32610, United States.ORCID 0000-0002-8281-4053
Sofia KokkaliariDepartment of Medicinal Chemistry and Center for Natural Products, Drug Discovery and Development (CNPD3), University of Florida, Gainesville, Florida 32610, United States.ORCID 0000-0002-4618-5640
Ranjala RatnayakeDepartment of Medicinal Chemistry and Center for Natural Products, Drug Discovery and Development (CNPD3), University of Florida, Gainesville, Florida 32610, United States.
Valerie J PaulSmithsonian Marine Station, Fort Pierce, Florida 34949, United States.ORCID 0000-0002-4691-1569
Hendrik LueschDepartment of Medicinal Chemistry and Center for Natural Products, Drug Discovery and Development (CNPD3), University of Florida, Gainesville, Florida 32610, United States.ORCID 0000-0002-4091-7492

Funding

Novel Targeted Anticancer Agents from Marine CyanobacteriaR01CA172310 · NCI · UNIVERSITY OF FLORIDA · PI HENDRIK LUESCH · 2013 to 2026
$5.8M
NMR console upgrade for structural biology and metabolomicsS10OD028753 · OD · UNIVERSITY OF FLORIDA · PI LONG, JOANNA R · 2020 to 2020
$600k
NCI NIH HHS R01 CA172310NIH HHS S10 OD028753
6 · The paper itself

Abstract

A new 14-membered ring brominated macrolide glycoside, named moorenaside (

Indexed as

Anti-Inflammatory AgentsCyanobacteriaGlycosidesKelch-Like ECH-Associated Protein 1NF-E2-Related Factor 2AnimalsHumansLipopolysaccharidesMacrophagesMiceMolecular StructureNF-kappa BNitric OxideRAW 264.7 CellsSignal TransductionAnti-Inflammatory AgentsGlycosidesKeap1 protein, mouseKelch-Like ECH-Associated Protein 1LipopolysaccharidesNfe2l2 protein, mouseNF-E2-Related Factor 2NF-kappa BNitric Oxide

Identifiers

PMID39315953
PMCPMC11519913

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.